Phase II trial of neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in patients with high-risk, clinically localized prostate cancer.

Trial Profile

Phase II trial of neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in patients with high-risk, clinically localized prostate cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2011

At a glance

  • Drugs Docetaxel; Tumour cell vaccine-GVAX
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Oct 2008 Actual patient number (6) added as reported by ClinicalTrials.gov.
    • 15 Oct 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 21 Jun 2008 Status changed from initiated to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top